γ-Lactones α,β- and β,γ-fused to carbocycles as novel antiproliferative drugs

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 19, 2008, Pages 5171-5173

  León, Leticia G ^a,b   Machín, Rubén P ^a,b   Rodríguez, Carmen M ^a   Ravelo, José L ^a   Martín, Víctor S ^a   Padrón, José M ^a,b  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b Madrid Spain   (Spain)

Author keywords

Lactones; Anticancer drugs; Drug discovery; Privileged structures; Ring closing metathesis

Indexed keywords

GAMMA LACTONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; RING CLOSING METATHESIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LACTONES; MOLECULAR STRUCTURE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52049115421     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.098     Document Type: Article

References (23)

1. The Merck Index, 13th ed.; Merck & Co., Inc.: Whitehouse Station, NY, 2001.
2. Dictionary of Organic Compounds, 6th ed.; Chapman & Hall/CRC: England, 1995.
3. Donadel O.J., Martín T., Martín V.S., and Padrón J.M. Bioorg. Med. Chem. Lett. 17 (2007) 18
4. Sun H.H., McEnroe F.J., and Fenical W. J. Org. Chem. 48 (1983) 1903
5. Midland S.L., Wing R.M., and Sims J.J. J. Org. Chem. 48 (1983) 1906
6. Herz W., Watanabe H., Miyazaki M., and Kishida Y. J. Am. Chem. Soc. 84 (1962) 2601
7. Kupchan S.M., Hemingway R.J., Werner D., Karim A., McPhail A.T., and Sim G.A. J. Am. Chem. Soc. 90 (1968) 3596
8. Sosa V.E., Oberti J.C., Gil R.R., Ruveda E.A., Goedken V.L., Gutierrez A.B., and Herz W. Phytochemistry 28 (1989) 1925
9. Hilmi F., Sticher O., and Heilmann J. Planta Med. 69 (2003) 462
10. Geissman T.A., and Griffin T.S. Phytochemistry 11 (1972) 833
11. Rodríguez C.M., Martín T., Ramírez M.A., and Martín V.S. J. Org. Chem. 59 (1994) 4461
12. Rodríguez C.M., Ravelo J.L., and Martín V.S. Org. Lett. 6 (2004) 4787
13. Ravelo J.L., Rodríguez C.M., and Martín V.S. J. Organomet. Chem. 691 (2006) 5326
14. All intermediates and final products gave satisfactory analytical and spectroscopic data in full accord with their assigned structures.
15. 50) represent the drug concentration at which PG is +50, 0, and -50, respectively,. Skehan P., Storeng P., Scudeiro D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107
16. Miranda P.O., Padrón J.M., Padrón J.I., Villar J., and Martín V.S. Chem. Med. Chem. 1 (2006) 323
17. Software-predicted lipophilicity of the compounds was calculated with the program New Clog P accessible via Internet. Available from: http://intro.bio.umb.edu/111-112/OLLM/111F98/newclogp.html.
18. Donadel O.J., Martín T., Martín V.S., Villar J., and Padrón J.M. Bioorg. Med. Chem. Lett. 15 (2005) 3536
19. Padrón J.M., Donadel O.J., León L.G., Martín T., and Martín V.S. Lett. Drug Des. Discov. 3 (2006) 29
20. Carrillo R., León L.G., Martín T., Martín V.S., and Padrón J.M. Bioorg. Med. Chem. Lett. 16 (2006) 6135
21. Carrillo R., León L.G., Martín T., Martín V.S., and Padrón J.M. Bioorg. Med. Chem. Lett. 17 (2007) 780
22. León L.G., Miranda P.O., Martín V.S., Padrón J.I., and Padrón J.M. Bioorg. Med. Chem. Lett. 17 (2007) 3087
23. Pungitore C.R., León L.G., García C., Martin V.S., Tonn C.E., and Padrón J.M. Bioorg. Med. Chem. Lett. 17 (2007) 1332